LZTS2

Across TCGA pan-cancer cohorts, LZTS2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LZTS2 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher LZTS2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LZTS2 expression acts as an unfavorable survival marker.

OV, KIRP, and BLCA are the cancer types where LZTS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	IV	0.170	0.758	.044	6	view →
KIRP	DFS	Median	All	0.181	0.768	.004	6	view →
BLCA	OS	Median	III,IV	0.197	0.684	.013	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LZTS2–OV (OS)

Open the OV breakdown →